Assembly Biosciences

Assembly Biosciences completed a guaranteed capital increase, grossing about $115 million. The company sold 3,924,624 common shares at $26.50 each, including 566,040 additional shares from the overallotment option, and one investor purchased pre-funded warrants for up to 415,000 shares at $26.499 per warrant. The stock traded at $28.75 after the placement. Assembly intends to use the net proceeds to finance the clinical development of its pipeline candidates and for general corporate purposes; analysts have price targets between $40 and $62. » Plus sur de.investing.com

Assembly Biosciences has placed 3,358,602 common shares at $26.50 per share and is also offering pre‑funded warrants for up to 415,000 shares at $26.499 each. Gross proceeds before fees are estimated at about $100 million; the syndicate banks have a 30‑day option for up to 566,040 additional shares. Closing is expected around May 26, 2026, and the proceeds are intended primarily to fund clinical development of pipeline candidates and for general corporate purposes. Guggenheim Securities, UBS and Mizuho are acting as book‑running managers; new and existing investors, including Gilead Sciences, are participating in the offering. » Plus sur de.investing.com

Assembly Biosciences will present interim clinical results from a randomized, blinded phase-1a study of ABI-6250, an oral hepatitis D virus entry inhibitor, at the EASL congress. The presentation covers safety, pharmacokinetics and pharmacodynamic activity after single and multiple dosing in healthy volunteers. The company plans to move directly into a phase-2 study later this year. The stock rose about 150% last year, market capitalization is roughly $490 million; analyst targets range from $40 to $62. » Plus sur de.investing.com